Key Highlights

  • 9.09% is the pre-market gain indicated for Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) on November 17, 2026, with shares indicated at USD 1.02 against a calculated prior close of USD 0.935.
  • 9.65 million USD in cash at September 30, 2026 compares with 7.56 million USD at December 31, 2025, according to the third quarter results the company released on November 12, 2026.
  • 2.58 million USD was the third quarter net loss, or USD 0.49 per share, versus a loss of USD 1.99 million, or USD 1.23 per share, in the third quarter of 2025.
  • 5,879,237 common shares were outstanding at September 30, 2026, up from 2,348,113 at December 31, 2025, which implies a calculated Market Value near USD 6.0 million at the indicated price.

What Moved Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in Pre-Market Trading on November 17, 2026 (+USD 0.085, +9.09%)

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) is indicated at USD 1.02 in pre-market trading on Tuesday, November 17, 2026, a pre-market move of +9.09%. The calculated prior close is USD 0.935 (price divided by 1.0909), and the calculated USD move is +USD 0.085. Using the 5,879,237 shares outstanding at September 30, 2026, the calculated market Capitalization is about USD 6.0 million. Pre-market Volume figures were not found, and pre-market sessions are typically thin.

The Rationale: No Fresh Catalyst Identified After the Third Quarter Update for Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)

No company announcement dated November 17, 2026 was identified in published coverage, so the move is not attributed to a specific event. As general context, the company released third quarter 2026 results at 7:01 a.m. ET on November 12, 2026, and the pre-market move may reflect continued repositioning around that update. Operationally, enrollment in the 20-patient PATHFINDER trial in multiply recurrent C. difficile infection began on September 29, 2026. The release also described a July 2026 FDA discussion on the totality of evidence for ibezapolstat after a single Phase 3 trial.

Valuation, Liquidity and Risks for Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)

Acurx is a clinical-stage company with no product Revenue reported. Third quarter Research and Development expense was USD 1.12 million versus USD 0.43 million a year earlier, while general and administrative expense eased to USD 1.52 million from USD 1.60 million. Nine-month net loss was USD 6.52 million, or USD 1.59 per share, and total liabilities were USD 2.99 million. Cash of USD 9.65 million covers roughly 3.7 quarters of the USD 2.63 million quarterly Operating Expense (calculated). The share count rose 150% in nine months (calculated), and about USD 1.5 million of gross proceeds came from an Equity line, so dilution risk remains. The release said international Phase 3 preparation is subject to obtaining appropriate financing. With a market value under USD 100 million, Volatility can be extreme.

Where Things Stand

The indicated pre-market price of USD 1.02 for Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) sits 9.09% above a calculated prior close of USD 0.935 on November 17, 2026. The company reported USD 9.65 million in cash, a third quarter net loss of USD 2.58 million and 5,879,237 shares outstanding at September 30, 2026. Pathfinder enrollment began on September 29, 2026, and the company remains dependent on financing for later-stage plans. No same-day catalyst was identified, so pre-market illiquidity, thin float and the recent Earnings update are general context rather than established causes.